BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Takeda's AI-crafted psoriasis pill succeeds in late-stage studies - 2Extraordinary Guinness World Records That Will Astound You
- 3The gay hockey show no one saw coming — and everyone is suddenly obsessed with
- 4Hamas hands over another body in the Gaza Strip
- 5From Fledgling to Master: Self-awareness in a Side interest
- How comfort foods trigger pleasure in our brains
- Figure out How to Remain Informed about the Most recent Open Record Extra Offers
- 6 Top of the line Lodgings All over The Planet, Which One Do You Concur With
- Instructions to Explore the Therapy Choices for Cellular breakdown in the lungs
- Manual for Famous Beverages 2024
- Working out at the airport? Some fliers can already smell the sweat.
- Trump administration plan to reduce access to some student loans angers nurses, health care groups
- Finding the Force of Mentorship: Self-awareness Through Direction
- Best Veggie lover Dinner: What's Your Plant-Based Pick?
